Red Sox face critical offseason decisions, including Bregman's opt-out and outfield moves, as they seek to bolster their lineup and manage roster depth.
Nvidia-backed CoreWeave's $9 billion acquisition of Core Scientific was rejected by shareholders, who saw the deal as undervaluing the company.
Trae Young sidelined for at least four weeks with a sprained MCL, Hawks' depth to be tested in his absence.
Red Sox face critical offseason decisions, including Bregman's opt-out and outfield moves, as they seek to bolster their lineup and manage roster depth.
Nvidia-backed CoreWeave's $9 billion acquisition of Core Scientific was rejected by shareholders, who saw the deal as undervaluing the company.
Trae Young sidelined for at least four weeks with a sprained MCL, Hawks' depth to be tested in his absence.